Guardant Health, Inc.

NasdaqGS:GH Stock Report

Market Cap: US$3.8b

Guardant Health Future Growth

Future criteria checks 1/6

Guardant Health is forecast to grow earnings and revenue by 38% and 16.8% per annum respectively. EPS is expected to grow by 33.4% per annum. Return on equity is forecast to be -216.4% in 3 years.

Key information

38.0%

Earnings growth rate

33.4%

EPS growth rate

Healthcare earnings growth18.9%
Revenue growth rate16.8%
Future return on equity-216.4%
Analyst coverage

Good

Last updated16 Dec 2024

Recent future growth updates

Recent updates

Why Guardant Health, Inc. (NASDAQ:GH) Could Be Worth Watching

Dec 31
Why Guardant Health, Inc. (NASDAQ:GH) Could Be Worth Watching

Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

Nov 08
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Oct 25
An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 24
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Aug 21

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Jul 31
Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jul 12
Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Guardant: Double-Digit Sales Projections Come At A Cost

Jun 06

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Jun 04
Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

May 14
Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Mar 29
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21
With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Nov 20
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 26
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Sep 05
A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Aug 15
Is Guardant Health (NASDAQ:GH) A Risky Investment?

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

May 28
A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Apr 05
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Dec 28
Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Earnings and Revenue Growth Forecasts

NasdaqGS:GH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,255-154-2976
12/31/20261,022-320-227-14016
12/31/2025848-379-264-18622
12/31/2024724-414-296-23922
9/30/2024692-512-274-254N/A
6/30/2024644-491-299-281N/A
3/31/2024604-461-301-281N/A
12/31/2023564-479-345-325N/A
9/30/2023536-432-363-337N/A
6/30/2023510-508-383-337N/A
3/31/2023482-665-418-355N/A
12/31/2022450-655-387-309N/A
9/30/2022431-606-388-296N/A
6/30/2022408-551-363-271N/A
3/31/2022391-419-309-221N/A
12/31/2021374-406-284-209N/A
9/30/2021344-409-249-191N/A
6/30/2021324-379-191-146N/A
3/31/2021298-336-143-107N/A
12/31/2020287-254-158-104N/A
9/30/2020271-185-129-75N/A
6/30/2020258-120-118-66N/A
3/31/2020245-77-102-56N/A
12/31/2019214-76-68-47N/A
9/30/2019184-76-60-43N/A
6/30/2019145-87-81-67N/A
3/31/2019111-97-89-70N/A
12/31/201891-85-92-72N/A
9/30/201878-75-85-64N/A
6/30/201867-84N/A-68N/A
3/31/201857-83N/A-65N/A
12/31/201750-89N/A-72N/A
12/31/201625-46N/A-37N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GH's revenue (16.8% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: GH's revenue (16.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GH is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 18:45
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guardant Health, Inc. is covered by 30 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael RyskinBofA Global Research
Derik de BruinBofA Global Research
Mark MassaroBTIG